1. Home
  2. AMRC vs NTLA Comparison

AMRC vs NTLA Comparison

Compare AMRC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ameresco Inc.

AMRC

Ameresco Inc.

HOLD

Current Price

$26.37

Market Cap

1.4B

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$13.46

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMRC
NTLA
Founded
2000
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Engineering & Construction
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
2010
2016

Fundamental Metrics

Financial Performance
Metric
AMRC
NTLA
Price
$26.37
$13.46
Analyst Decision
Strong Buy
Buy
Analyst Count
8
20
Target Price
$37.88
$20.45
AVG Volume (30 Days)
418.0K
3.6M
Earning Date
03-02-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.43
EPS
0.49
N/A
Revenue
$1,769,928,000.00
$67,671,000.00
Revenue This Year
$10.66
N/A
Revenue Next Year
$8.93
$62.75
P/E Ratio
$54.77
N/A
Revenue Growth
28.76
16.92
52 Week Low
$8.49
$5.90
52 Week High
$44.93
$28.24

Technical Indicators

Market Signals
Indicator
AMRC
NTLA
Relative Strength Index (RSI) 41.58 52.76
Support Level $26.29 $12.55
Resistance Level $31.12 $14.61
Average True Range (ATR) 1.60 0.72
MACD 0.03 -0.07
Stochastic Oscillator 30.56 41.52

Price Performance

Historical Comparison
AMRC
NTLA

About AMRC Ameresco Inc.

Ameresco Inc is an energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the energy transition. Its comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. Its solutions range from upgrades to facility's energy infrastructure to the development, construction and operation of renewable energy plants combined with tailored financial solutions. Its segments include North America Regions, U.S. Federal, Renewable Fuels, Europe, and Others. The majority of the revenue is derived from North America Regions segment.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: